Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overview of melanoma vaccines and promising approaches.

Current oncology reports - 1 Sept 2004

Panelli Monica C, Wang Ena, Monsurrò Vladia, Jin Ping, Zavaglia Katia, Smith Kina, Ngalame Yvonne, Marincola Francesco M

Abstract excerpt

It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics. Melanoma vaccines can reproducibly induce cytotoxic T lymphocyte (CTL) responses better than any other anticancer therapy. Anticancer vaccines have been labeled by some as ineffective for the simple reason that they only rarely lead to cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Immunotherapy

Share to Melanoma

Share to Skin Neoplasms

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 15291987
DOI: 10.1007/s11912-004-0069-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overview of melanoma vaccines and promising approaches.PMID 15291987Read ↗

Strategies for developing and optimizing cancer vaccinesSemantic proximity Read ↗

Dendritic cell vaccines in melanoma: from promise to proof?Semantic proximity Read ↗

T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Semantic proximity Read ↗

Advancement insights in cancer vaccines: mechanisms, types, and clinical applicationsSemantic proximity Read ↗

Vaccines in oncology: background and clinical potential.Semantic proximity Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

Impact of checkpoint blockade on cancer vaccine–activated CD8+ T cell responsesSemantic proximity Read ↗

Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.Semantic proximity Read ↗

PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma VaccinesSemantic proximity Read ↗

Melanoma antigens recognised by CD8+ and CD4+ T cells.Semantic proximity Read ↗

New approaches to the development of adenoviral dendritic cell vaccines in melanoma.Semantic proximity Read ↗

Adoptive T-Cell Therapy for Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.